RDC No. 185/2001 Repealed by RDC No. 751/2022: Outdated Citations and the Revision Trap

1. Key takeaways

RDC n° 185/2001 is no longer a valid basis for medical devices in Brazil: its repeal is written in Article 66 of RDC n° 751/2022, taking effect simultaneously with that resolution on March 1, 2023 (Article 67). All current classification, notification and registration rules are now governed exclusively by RDC n° 751/2022.

GRZAN’s judgment: Article 66 disposed of RDC n° 185/2001, RDC n° 15/2014, RDC n° 40/2015, RDC n° 207/2006 and RE n° 1554/2002 — 5 old rules in one stroke — plus parts of IN n° 4/2012, for 6 items in total. Any secondary material still describing the current system through these numbers should be discarded.

2. Legal basis

• Classification, notification and registration of medical devices, and labeling and instruction-for-use requirements — RDC n° 751/2022, resolution of September 15, 2022, Articles 66, 67, 4 (item VIII) and 11
• Brazilian good manufacturing practices — RDC n° 665/2022, published March 30, 2022 (DOU March 31, 2022), Articles 137 and 138
• Grant and renewal of good manufacturing practice certificates — RDC n° 687/2022, Articles 16 and 17 (effective June 1, 2022)
• Rules for in vitro diagnostic medical devices — RDC n° 830/2023, published in DOU No. 234 of December 11, 2023, Article 71
• Amendments to RDC n° 751/2022 — RDC n° 777/2023, resolution of March 1, 2023 and effective the same day, Articles 2, 16, 22, 39 and 40 [practical estimate, subject to ANVISA publication]

3. Expert insights

Why do materials still cite RDC n° 185/2001 so many years later? GRZAN observes three causes: writing onward from an old translation without ever re-checking the new law; translating the main text but not the repeal clauses, so a legislative tail like Article 66 gets skipped; and the fact that procedural clauses changed little, so the old text looks deceptively alive. All three share one root: nobody treated the repeal list as part of the norm itself, even though legally it carries the same force as any other article.

The harm is not academic. Timeline estimates built on the old law will understate the CBPF critical path; budgets built on the old law will not fit the new fee structure; and when an audit or platform review arrives, citing a repealed number directly exposes how stale the documentation is. In GRZAN’s experience the correction always costs more than the original verification would have — the error propagates through quotations, templates and training material before anyone notices it.

A still more frequent error is recording only who repealed a rule, never who amended it. RDC n° 751/2022 itself has been amended by RDC n° 777/2023 (resolution of March 1, 2023, effective the same day): Article 2, §3 was changed so that custom-made devices (sob medida) fall outside RDC n° 751; Article 16 corrected the reference to IN n° 74/2020; Article 22 adjusted filing requirements related to immediate implementation changes (that article covers labeling and outer packaging of devices and IVDs, and has nothing to do with instruction-for-use upload deadlines) [secondary materials often repeat the claim that the IFU upload deadline was deleted by that article; primary verification: the upload deadlines are set by Article 33, §§5–6, with starting points of 30 days after DOU publication and 180 days after implementation of the change, both currently in force]; Article 39 narrowed the grounds for suspending manufacture, import, distribution, sale or use, and revoked the original Article 40. The existence of that resolution is confirmed by Brazil’s WTO TBT notification, while its article-by-article content comes from secondary compilation — GRZAN marks the verification level here, and a check against the DOU and the ANVISA legislative library is required before formal submission. [practical estimate, subject to ANVISA publication]

Two other outdated citations must be replaced as well: RDC n° 102/2016 was repealed by Article 47 of RDC n° 903/2024 (in the same batch as RDC n° 118/2016, RDC n° 233/2018 and Article 13 of RDC n° 438/2020) [practical estimate, subject to ANVISA publication]; and on the BGMP side, RDC n° 16/2013 and IN n° 8/2013 were superseded by Article 137 of RDC n° 665/2022.

When GRZAN takes over legacy projects, outdated numbers cluster in three places: the provision names cited in quotations, the regulatory references inside old IFUs and label templates, and the product materials supplied by distributors. Unless these are cleaned proactively, registration review and platform audits will surface them repeatedly.

GRZAN’s method treats repeal and amendment as two separate checks: for any Brazilian regulation, first read the tail for a repeal list, then search for later amendments.

GRZAN also recommends logging the reason of invalidity in the cross-reference table: repealed by Article 66, scope carved away by RDC n° 830/2023, or modified by a later resolution. Different reasons point to different replacement provisions; recording numbers without reasons means re-running the same research six months later.

4. Practical recommendations

• Maintain an internal repeal-and-amendment cross-reference table mapping old numbers to current ones, re-checked quarterly against the DOU and the ANVISA legislative library.
• Replace any document that still carries RDC n° 185/2001, RDC n° 16/2013, IN n° 8/2013 and similar numbers, noting the verification date.
• Cite in the four-element format — regulation name, number, publication date, provision number — for batch checking.
• Before citing any specific provision of RDC n° 751/2022, confirm whether RDC n° 777/2023 has modified it.
• Run one numbering audit across quotations, IFUs and label templates so stale bases never reach customer deliverables.
• Apply the same numbering checks to technical files supplied by foreign manufacturers, preventing upstream errors from flowing downstream.
• Give the table at least four columns — old number / reason of invalidity / current number / last review date — and leave no blank cells.

5. Verification checklist

• □ All repeal targets listed in Article 66 of RDC n° 751/2022 have been confirmed
• □ RDC n° 185/2001 has been removed from all external documents
• □ RDC n° 665/2022 has been confirmed to supersede RDC n° 16/2013 and IN n° 8/2013
• □ RDC n° 687/2022 has been confirmed to supersede RDC n° 183/2017
• □ The current amendments of RDC n° 777/2023 to RDC n° 751/2022 have been checked

Regulatory information verified as of October 29, 2026.

GRZAN Regulatory Team

GRZAN provides registration and compliance support for medical device and IVD manufacturers entering the Brazilian market, covering regulatory mapping and numbering audits, ANVISA dossier preparation, CBPF coordination and post-market compliance. For assistance with Brazilian regulatory requirements, contact info@grzanglobal.com.